Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 21 for:    "Depressive Disorder" [DISEASE] AND Behavioral AND Spanish | ( Map: Spain )

Efficacy of a Blended Low Intensity Internet-delivered Psychological Program in Patients With Multimorbidity in Primary Care.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03426709
Recruitment Status : Recruiting
First Posted : February 8, 2018
Last Update Posted : August 8, 2019
Sponsor:
Collaborator:
Carlos III Health Institute
Information provided by (Responsible Party):
Javier Garcia Campayo, Hospital Miguel Servet

Tracking Information
First Submitted Date  ICMJE February 2, 2018
First Posted Date  ICMJE February 8, 2018
Last Update Posted Date August 8, 2019
Actual Study Start Date  ICMJE November 26, 2018
Estimated Primary Completion Date April 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 8, 2018)
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Baseline ]
    In the Intervention group. The Patient Health Questionnaire (PHQ-9) is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Baseline ]
    In the TAU control group. The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 3 months follow up in the intervention group ]
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 3 months follow up in the TAU control group ]
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 6 months follow up in the intervention group ]
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 6 months follow up in the TAU control group ]
    In the Intervention group. The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ scores ≥ 10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. The possible range is 0-27.
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Baseline ]
    In the Intervention group
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Baseline ]
    In the TAU control group
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 3 months follow up in the intervention group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 3 months follow up in the TAU control group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 6 months follow up in the intervention group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 6 months follow up in the TAU control group ]
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: Baseline ]
    In the Intervention group. The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: Baseline ]
    In the TAU control group. The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
    The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
    The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: 3 months follow up in the intervention group ]
    The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: 3 months follow up in the TAU control group ]
    The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: 6 months follow up in the intervention group ]
    The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Roland Morris Disability Questionnaire (RMDQ) [ Time Frame: 6 months follow up in the TAU control group ]
    The Roland Morris Disability Questionnaire (RMDQ) consists of 24 statements relating to the person's perceptions of their back pain and associated disability. This includes items on physical ability/ activity (15), sleep/rest (3), psychosocial (2), household management (2), eating (1) and pain frequency (1). It is designed to take approximately 5 minutes to complete, without any assistance from the administrator. The RMDQ is scored by adding up the number of items checked by the patient (1 if is checked, 0 if is not). The score can range from 0 (no disability) to 24 (maximal disability).
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Baseline ]
    In the Intervention group
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Baseline ]
    In the TAU control group
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 3 months follow up in the intervention group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 3 months follow up in the TAU control group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 6 months follow up in the intervention group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 6 months follow up in the TAU control group ]
Original Primary Outcome Measures  ICMJE
 (submitted: February 2, 2018)
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Baseline ]
    In the Intervention group
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Baseline ]
    In the TAU control group
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 3 months follow up in the intervention group ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 3 months follow up in the TAU control group ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 6 months follow up in the intervention group ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: 6 months follow up in the TAU control group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Baseline ]
    In the Intervention group
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Baseline ]
    In the TAU control group
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 3 months follow up in the intervention group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 3 months follow up in the TAU control group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 6 months follow up in the intervention group ]
  • Visual Analog Scale (0-100) or Numeric Pain Scale (0-10) [ Time Frame: 6 months follow up in the TAU control group ]
  • ROLAND-MORRIS Scale [ Time Frame: Baseline ]
    In the Intervention group
  • ROLAND-MORRIS Scale [ Time Frame: Baseline ]
    In the TAU control group
  • ROLAND-MORRIS Scale [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • ROLAND-MORRIS Scale [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • ROLAND-MORRIS Scale [ Time Frame: 3 months follow up in the intervention group ]
  • ROLAND-MORRIS Scale [ Time Frame: 3 months follow up in the TAU control group ]
  • ROLAND-MORRIS Scale [ Time Frame: 6 months follow up in the intervention group ]
  • ROLAND-MORRIS Scale [ Time Frame: 6 months follow up in the TAU control group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Baseline ]
    In the Intervention group
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Baseline ]
    In the TAU control group
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 3 months follow up in the intervention group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 3 months follow up in the TAU control group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 6 months follow up in the intervention group ]
  • Diabetes control measured by VR d= Hb glucosidal [ Time Frame: 6 months follow up in the TAU control group ]
Change History Complete list of historical versions of study NCT03426709 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 8, 2018)
  • Sociodemographic data Gender, age, marital status, education, occupation, economical level [ Time Frame: Baseline ]
    In the Intervention group and the TAU control group
  • The Mini-International Neuropsychiatric Interview (MINI) [ Time Frame: Baseline ]
    In the Intervention group and the TAU control group. This is a short structured diagnostic psychiatric interview that yields key DSM-IV and ICD-10 diagnoses. MINI can be administered in a short period of time and clinical interviewers need only a brief training. The MINI has been translated and validated in Spanish.
  • Health Survey 12 (SF-12) [ Time Frame: Baseline ]
    In the Intervention group
  • Health Survey 12 (SF-12) [ Time Frame: Baseline ]
    In the TAU control group
  • Health Survey 12 (SF-12) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Health Survey 12 (SF-12) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Health Survey 12 (SF-12) [ Time Frame: 3 months follow up in the intervention group ]
  • Health Survey 12 (SF-12) [ Time Frame: 3 months follow up in the TAU control group ]
  • Health Survey 12 (SF-12) [ Time Frame: 6 months follow up in the intervention group ]
  • Health Survey 12 (SF-12) [ Time Frame: 6 months follow up in the TAU control group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Baseline ]
    In the Intervention group
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Baseline ]
    In the TAU control group
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 3 months follow up in the intervention group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 3 months follow up in the TAU control group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 6 months follow up in the intervention group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 6 months follow up in the TAU control group ]
Original Secondary Outcome Measures  ICMJE
 (submitted: February 2, 2018)
  • Sociodemographic data Gender, age, marital status, education, occupation, economical level [ Time Frame: Baseline ]
    In the Intervention group and the TAU control group
  • The Mini-International Neuropsychiatric Interview (MINI) [ Time Frame: Baseline ]
    In the Intervention group and the TAU control group
  • Health Survey 12 (SF-12) [ Time Frame: Baseline ]
    In the Intervention group
  • Health Survey 12 (SF-12) [ Time Frame: Baseline ]
    In the TAU control group
  • Health Survey 12 (SF-12) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Health Survey 12 (SF-12) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Health Survey 12 (SF-12) [ Time Frame: 3 months follow up in the intervention group ]
  • Health Survey 12 (SF-12) [ Time Frame: 3 months follow up in the TAU control group ]
  • Health Survey 12 (SF-12) [ Time Frame: 6 months follow up in the intervention group ]
  • Health Survey 12 (SF-12) [ Time Frame: 6 months follow up in the TAU control group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Baseline ]
    In the Intervention group
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Baseline ]
    In the TAU control group
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Post-treatment 8 weeks from baseline in the intervention group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: Post-treatment 8 weeks from baseline in the TAU control group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 3 months follow up in the intervention group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 3 months follow up in the TAU control group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 6 months follow up in the intervention group ]
  • Client Service Receipt Inventory (CSRI) [ Time Frame: 6 months follow up in the TAU control group ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy of a Blended Low Intensity Internet-delivered Psychological Program in Patients With Multimorbidity in Primary Care.
Official Title  ICMJE Efficacy of a Blended Low Intensity Internet-delivered Psychological Program in Patients With Multimorbidity in Primary Care. A Randomized Clinical Trial.
Brief Summary The aim of this study is to assess the efficacy in Primary Care (PC) of a low intensity psychological intervention applied using Information and communication technologies (ICTs) for the treatment of multimorbidity in PC (depression and diabetes/low back pain) by a randomized controlled trial (RCT). A protocol will be design that combines face to face intervention with a supporting online program that will be tried in a RCT conducted in 3 different regions (Andalucía, Aragón, y Baleares). Our main hypothesis is that improved usual care combined with psychological therapy applied by ICTs, will be more efficacious to improve the symptomatology of multimorbidity, compared to a group with only improved treatment as usual six months after the end of treatment.
Detailed Description Although multimorbidity is highly prevalent, health care systems are designed for the management individual diseases. New strategies are needed to help general practitioners to provide appropriate personalized care to patients. The World Health Organization (WHO) has included comorbidity between depression and a chronic disease as one of the 10 main priorities in global public health. Studies in meta-analysis confirm that the 2 main interventions of first choice for depression are pharmacotherapy and/or psychotherapy, with similar results in the short term but superior in the long term for psychological treatments. Given the difficulty of delivering face to face psychological treatments (high costs) alternative models of delivering treatments have been proposed, emphasizing the role of technologies like Internet. The aim of this study is to assess the efficacy in Primary Care (PC) of a low intensity psychological intervention (8 weeks) applied using Information and communication technologies (ICTs) for the treatment of multimorbidity in PC (depression and diabetes/low back pain) by a randomized controlled trial (RCT). Our main hypothesis is that improved usual care combined with psychological therapy applied by ICTs, will be more efficacious to improve the symptomatology of multimorbidity, compared to a group with only improved treatment as usual six months after the end of treatment. A protocol will be design that combines face to face intervention with a supporting online program that will be tried in a RCT conducted in 3 different regions (Andalucía, Aragón, y Baleares). 300 participants diagnosed with depression and diabetes/low back pain will participate in the RCT. It´s proposed a coordinated study by 4 highly experienced groups with great possibilities of translation and transference to usual clinical practice.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Depression
  • Chronic Disease (Diabetes/Low Back Pain)
Intervention  ICMJE Behavioral: Low intensity Internet-delivered psychotherapy
The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
Study Arms  ICMJE
  • Experimental: Low intensity Internet-delivered psychotherapy
    improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies) in groups of 8-12 people.
    Intervention: Behavioral: Low intensity Internet-delivered psychotherapy
  • No Intervention: Improved Treatment-as-usual (TAU)
    In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 2, 2018)
300
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2020
Estimated Primary Completion Date April 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Be adult
  • Willingness to participate in the study and signing informed consent
  • Ability to understand oral and written Spanish.
  • DSM-5 diagnose of Major Depression or Dysthymia, mild or moderate depression expressed as score lower than 14 in the Patient Health Questionnaire (PHQ-9)
  • Duration of depressive symptoms 2 months or more
  • Diagnosis of one of the following two conditions: Diabetes (Diagnosis according to criteria of the American Diabetes Association (ADA)) or low back pain (Diagnosis of non-specific chronic low back pain according to the definition established by the Clinical Practice Guide of the European Program COST B-13 (CPG COST B-13) with a duration of at least 6 months)
  • To have and to handle the computer, internet and mobile phone

Exclusion Criteria:

  • Any diagnose of disease that may affect central nervous system (brain pathology, traumatic brain injury, dementia, etc.),
  • Other psychiatric diagnoses or acute psychiatric illness (substance dependence or abuse, history of schizophrenia or other psychotic disorders, eating disorders, etc.), except for anxious pathology or personality disorders
  • Any medical, infectious or degenerative disease that may affect mood
  • Presence of delusional ideas or hallucinations consistent or not with mood
  • Suicide risk
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Javier García-Campayo +34976765500 jgarcamp@gmail.com
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03426709
Other Study ID Numbers  ICMJE PI16/00962
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Javier Garcia Campayo, Hospital Miguel Servet
Study Sponsor  ICMJE Javier Garcia Campayo
Collaborators  ICMJE Carlos III Health Institute
Investigators  ICMJE
Principal Investigator: Javier García-Campayo Miguel Servet Hospital and University os Zaragoza, Spain
PRS Account Hospital Miguel Servet
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP